A vaccine for the respiratory virus RSV will soon be available for people aged 60 and above. The therapeutic goods administration has approved the use of the vaccine for people with a prescription, to help stop the potentially deadly virus in its tracks. Most cases of the virus are mild, but some can lead to chest infections like bronchiolitis and pneumonia.